Seattle Genetics (ticker: SGEN, exchange: NASDAQ Global Market (.O))
News Release -
26-Jul-2011
Seattle Genetics to Host Conference Call and Webcast Discussion of
Second Quarter 2011 Financial Results on August 4, 2011BOTHELL, Wash., Jul 26, 2011 (BUSINESS WIRE) -- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report
its second quarter 2011 financial results on Thursday, August 4, 2011,
after the close of financial markets. Following the announcement,
company management will host a conference call and webcast discussion of
the results and provide a general corporate update. Access to the event
can be obtained as follows:
LIVE access on Thursday, August 4, 2011
1:30 p.m. Pacific Time (PT) / 4:30 p.m. Eastern Time (ET)
REPLAY access
-
Telephone replay will be available beginning at approximately 3:30
p.m. PT on Thursday, August 4, 2011, through 3:30 p.m. PT on Monday,
August 8, 2011, by calling (800) 406-7325 (domestic) or (303) 590-3030
(international); conference ID 4459836
-
Webcast replay will be available on the Seattle Genetics website at http://www.seattlegenetics.com
in the Investors
and News section
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development
and commercialization of monoclonal antibody-based therapies for the
treatment of cancer and autoimmune disease. The U.S. Food and Drug
Administration has granted priority review to Biologics License
Applications for its lead product candidate, ADCETRIS(TM), for the
treatment of relapsed or refractory Hodgkin lymphoma and relapsed or
refractory systemic anaplastic large cell lymphoma, with a PDUFA date of
August 30, 2011. ADCETRIS is being developed in collaboration with
Millennium: The Takeda Oncology Company. In addition, Seattle Genetics
has five other clinical-stage programs: SGN-75, ASG-5ME, ASG-22ME,
dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for
its ADC technology with a number of leading biotechnology and
pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics,
Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and
Progenics, as well as ADC co-development agreements with Agensys, an
affiliate of Astellas, and Genmab. More information can be found at http://www.seattlegenetics.com.
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the company's
expectations for regulatory approval and commercial launch of ADCETRIS.
Actual results or developments may differ materially from those
projected or implied in these forward-looking statements. Factors that
may cause such a difference include risks that data from our pivotal
Hodgkin lymphoma trial and phase II systemic ALCL trial of ADCETRIS will
not support marketing approval for the submitted indications. More
information about the risks and uncertainties faced by Seattle Genetics
is contained in the company's 10-Q for the quarter ended March 31, 2011
filed with the Securities and Exchange Commission. Seattle Genetics
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE: Seattle Genetics, Inc.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com |
Seattle Genetics
